Navigation Links
Access Pharmaceuticals Announces the European Launch of MuGard(TM) by its European Partner, SpePharm
Date:4/22/2009

ion and treatment of mucositis recommend the use of a preventive oral care regimen as part of routine supportive care along with a therapeutic oral care regimen if mucositis develops. The market for the treatment of oral mucositis is estimated to be in excess of $1 billion world-wide.

MuGard forms a protective coating over the oral mucosa when swirled gently around the mouth. In a comparison of cancer patients receiving standard mucositis care with those patients receiving MuGard, the incidence and severity of mucositis was significantly lower in the MuGard treated group using a validated scale for the assessment of oral mucositis.

About Access:

Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company that develops and commercializes propriety products for the treatment and supportive care of cancer patients. Access' products include ProLindac(TM), currently in Phase 2 clinical testing of patients with ovarian cancer, and MuGard(TM) for the management of patients with mucositis. The company also has other advanced drug delivery technologies including Cobalamin(TM)-mediated targeted delivery and oral drug delivery, its proprietary nanopolymer delivery technology based on the natural vitamin B12 uptake mechanism; Angiolix(R), a humanized monoclonal antibody which acts as an anti-angiogenesis factor and is targeted to breast cancer; Prodrax(R), a non-toxic prodrug which is activated in the hypoxic zones of solid tumors to kill cancer cells; Alchemix, a chemotherapeutic agent that combines multiple modes of action to overcome drug resistance. Access is also developing Phenylbutyrate ("PB"), an HDAC inhibitor and differentiating agent currently a Phase 2 clinical candidate. Access recently announced the acquisition of MacroChem Corporation. This acquisition provides Access with three additional late-stage product candidates. Pexiganan, a novel topical anti-infective for the treatment of diabetic foot infection
'/>"/>

SOURCE Access Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Access Pharmaceuticals Presents New Data on ProLindac(TM) at the 2009 AACR Annual Meeting
2. Insmed Announces Agreement With IDIS to Manage Expanded Access Programs for IPLEX(TM)
3. New organic material may speed Internet access
4. Biogenerics Legislation Provides Critical Pathway to Affordable Access for Patients with Chronic and Complex Conditions
5. GPhA Statement on the Introduction of the Bipartisan Biogenerics Consensus Bill: Promoting Innovation and Access to Life-Saving Medicine Act
6. Sigma-Aldrich Streamlines Access to Advanced Stem Cell Research Portfolio and Opens Stem Cell Biology Community Through New Web Portal
7. Campbell Alliance Brand Management Practice to Present at EyeForPharmas Oncology Summit USA and Oncology Market Access Europe Conference
8. Schering-Plough Announces Collaboration With World Health Organization to Provide Access to Pandemic Influenza Vaccine Technology to Developing Countries
9. London-Based Double Helix Consulting Launches US Division for Strategic Pricing, Reimbursement and Market Access Solutions
10. Amgens Breakaway from Cancer Initiative Expands to Help Cancer Patients Access Broad Spectrum of Cancer Resources and Services
11. SurgiQuest Signs a Development and Supply Agreement with Intuitive Surgical for MIS Access Utilizing the AirSeal(TM) Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... , May 23, 2013 PuraMed ... developer, and marketer of over-the-counter (OTC) medicinal and ... research opinion on the company based on low ... , Non-Prescription, All Natural Product to Treat ... Product Outperforms #1 Prescription Competitor , Currently ...
(Date:5/23/2013)... (PRWEB) May 23, 2013 PI’s ... wide and provide 15 mm travel range with ... The small dimensions make these new positioners the ... spaces. A vacuum rated version is also available. ... specifications and datasheets can be found at: , ...
(Date:5/23/2013)... 23, 2013 Virobay, Inc. today announced that ... reached an important milestone, as Virobay has now initiated ... selective cathepsin S inhibitor.   The first ... placebo-controlled study designed to evaluate the safety, tolerability, pharmacokinetics ... adults. "The initiation of this Phase 1 ...
(Date:5/23/2013)... Z Trim Holdings, Inc. (OTC Markets: ZTHO), ... of industries, announced that Chef Erin Ryan ... year,s National Restaurant Association ("NRA") NRA Show, which was ... Research Chefs Association.  Chef Ryan spoke on the subject ... and the Ugly," joining four other prestigious panelists including: ...
Breaking Biology Technology:PuraMed BioScience (PMBS) Issued Alert Based on Market Cap of $721,756 2PuraMed BioScience (PMBS) Issued Alert Based on Market Cap of $721,756 3Precision Positioning System Uses Miniaturezed Piezo Linear Motor: LPS-24 Linear Stage by PI 2Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 2Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 3Z Trim's Chef Erin Ryan sits on Expert Panel at NRA Show 2Z Trim's Chef Erin Ryan sits on Expert Panel at NRA Show 3
... Fla., July 2 Bioheart, Inc. (Nasdaq:,BHRT) a ... of,autologous (patient-derived) cell therapies and devices for the ... it has been added to the,Russell Microcap Index ... of U.S. and global equity indexes on June ...
... Pharma, a leading provider of,knowledge management solutions to ... that the Aureus Pharma 2008 User Symposium will,be ... This symposium follows last year,s highly successful ... pharmaceutical and biotech customers,from both Europe and North ...
... 2 Research conducted at The,Walter and ... to a,major licensing agreement signed between Australian ... Merck,Serono., Under the Development and Licensing ... treatments for multiple sclerosis (MS) and other ...
Cached Biology Technology:Bioheart, Inc., Added to Russell Microcap Index 2Aureus Pharma Announces Date of 2008 Annual User Symposium 2MS Drug Development Agreement Based on WEHI's Medicinal Chemistry 2
(Date:5/23/2013)... fastest growing open-access publishers, announces the launch of ... Biotechnology . , A broad scope journal ... Biotechnology will provide a single open-access platform ... to be disseminated and discussed. , ... an open-science and interactive web platform for the ...
(Date:5/23/2013)... an age when microbial pathogens are growing increasingly resistant ... a team of Wisconsin scientists has synthesized a potent ... that cause staph infections. , Writing online in the ... group led by University of Wisconsin-Madison chemistry Professor Helen ... sensing" behavior of Staphylococcus aureus , a bacterium ...
(Date:5/22/2013)... Lung Screening Trial (NLST) investigators also conclude that ... with low-dose computed tomography (LDCT) versus chest X-ray ... paper is achievable at experienced screening centers in ... information to share with their patients about the ... following today,s publication in the New England ...
Breaking Biology News(10 mins):Frontiers launches new open-access journal in Bioengineering and Biotechnology 2University of Wisconsin chemists find new compounds to curb staph infection 2NLST: CT detects twice as many lung cancers as X-ray at initial screening exam 2NLST: CT detects twice as many lung cancers as X-ray at initial screening exam 3
... DC Could some women who naturally produce excess ... developing breast cancer? Results of a new animal study ... Georgetown Lombardi Comprehensive Cancer Center, a part of Georgetown ... August 15 Cancer Research, the investigators say ...
... North American Societies provides a comprehensive and in-depth documentation ... adapting to the varied ecosystems of North America during ... of recurrent themes and questions that have shaped debates ... impact on their local environments throughout the Holocene. ...
... (Vancouver August 11, 2011) Pregnant women taking prenatal ... new Vancouver-based study led by the Child & Family Research ... Canadian Journal of Public Health . The study ... reported taking supplements containing vitamin D, many were vitamin D ...
Cached Biology News:Higher estrogen production in the breast could confer greater cancer risk than thought 2Higher estrogen production in the breast could confer greater cancer risk than thought 3Pregnant women in Vancouver may not be getting enough vitamin D 2
... (RNase III) from E. coli is an ... to dsRNA fragments that have 2-base, 3'-overhangs. ... dsRNA fragments of 12-15 bp. RNase ... canonical ribonucleotides as well as DuraScript™ RNA, ...
Rabbit polyclonal to Peptide E ( Abpromise for all tested applications)....
Mouse monoclonal [6911] to E. coli K99 pilus ( Abpromise for all tested applications)....
...
Biology Products: